Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to two new employees to purchase an aggregate of 24,000 shares, effective February 2, 2026. The options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $25.65.
The awards were approved by the Compensation Committee and issued under the company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – OLMA
On the day this news was published, OLMA gained 0.77%, reflecting a mild positive market reaction. Argus tracked a peak move of +18.3% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $17M to the company's valuation, bringing the market cap to $2.17B at that time. Trading volume was elevated at 2.6x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
OLMA slipped -0.27% while close peers were mixed: ARVN and SAGE were down, BCAX and VSTM were up, and ORKA was slightly lower. This points to stock-specific rather than broad sector-driven action.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Inducement grants | Neutral | -0.7% | Inducement options for 8 new employees under 2022 Inducement Plan. |
| Jan 05 | Conference participation | Positive | -0.7% | Announcement of presentation at J.P. Morgan Healthcare Conference. |
| Dec 02 | Inducement grants | Neutral | +0.4% | Inducement options for two employees totaling 65,000 shares. |
| Nov 21 | Conference participation | Positive | +8.1% | Participation in Evercore Healthcare Conference fireside chat. |
| Nov 20 | Equity offering | Negative | +13.3% | Closing of $218.5M common stock offering at $19.00 per share. |
Inducement grant announcements have historically coincided with relatively small price moves, while financing and conference participation have seen larger positive reactions.
Over the past few months, OLMA has mixed routine HR and investor-relations updates with a significant equity financing. Prior inducement grant announcements on Dec 2, 2025 and Jan 5, 2026 involved similar option terms and produced modest price moves within ±1%. Conference participation in late 2025 correlated with a stronger 8.11% gain, while the $218.5M public offering on Nov 20, 2025 saw a notable 13.28% rise. Today’s small inducement grants fit the pattern of routine compensation-related news.
Market Pulse Summary
This announcement details standard inducement stock options for two new employees, covering 24,000 shares at an exercise price of $25.65 with a 4-year vesting schedule and 10-year term under the 2022 Inducement Plan. Similar grants on Dec 2, 2025 and Jan 5, 2026 also followed Nasdaq Listing Rule 5635(c)(4). Investors may monitor how such equity awards, along with recent insider sales and executive changes, affect the overall ownership and incentive structure over time.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. Not financial advice.
SAN FRANCISCO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 24,000 shares of the Company's common stock, effective as of February 2, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
